PDCD1LG2 and COVID-19: In this context, we can speculate that the decrease or lack of response of PD‐L2 during the acute phase of COVID‐19 may contribute to the immune dysfunction that characterizes this disease, which is observed by the altered presence of CD4+ T‐cells in post‐COVID‐ILD patients with a profile of up‐sPDL‐2 levels and consequently, may disturb the systemic or local microenvironment of cytokines.